TOP > 外国特許検索 > TGFΒ INHIBITOR CONTAINING REIC/Dkk-3 PROTEIN AS ACTIVE INGREDIENT

TGFΒ INHIBITOR CONTAINING REIC/Dkk-3 PROTEIN AS ACTIVE INGREDIENT NEW

外国特許コード F180009313
整理番号 (S2016-0842-N0)
掲載日 2018年1月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP022588
国際公開番号 WO 2017217556
国際出願日 平成29年6月19日(2017.6.19)
国際公開日 平成29年12月21日(2017.12.21)
優先権データ
  • 特願2016-121187 (2016.6.17) JP
発明の名称 (英語) TGFΒ INHIBITOR CONTAINING REIC/Dkk-3 PROTEIN AS ACTIVE INGREDIENT NEW
発明の概要(英語) The purpose of the present invention is to provide a medicine for preventing or treating TGFβ-related diseases by inhibiting signal transduction of TGFβ. Provided are: a TGFβ inhibitor that contains, as an active ingredient, the REIC/Dkk-3 protein, a partial protein including a Cys-rich domain thereof, or DNA encoding those; and a prophylactic or therapeutic agent for TGFβ-related diseases, containing said TGFβ inhibitor.
特許請求の範囲(英語) [claim1]
1. Protein or a Cys-rich REIC/Dkk-3 LDLRal DNA encoding a protein or portion thereof includes as an active ingredient TGF β inhibitor.
[claim2]
2. Cys-rich REIC/Dkk-3 protein or a portion including a domain of the protein as an active ingredient according to claim 1 TGF β inhibitor, in a concentration range of 50nm or more in the dose action, depending on the concentration of TGF β to interact with its receptor and to interfere with the reactions, according to claim 1 TGF β of the inhibitor.
[claim3]
3. Action at higher dose dosage, and reaction to interact with its receptor TGF β completely but does not inhibit, according to claim 1 or 2 TGF β inhibitor.
[claim4]
4. 375nm even more Antivenin action, to interact with its receptor TGF β and completely and does not inhibit a reaction, according to claim 3 TGF β of the inhibitor.
[claim5]
5. To any one of claims 1-4 TGF β inhibitor, anti-tumor immunity activator.
[claim6]
6. To any one of claims 1-4 TGF β inhibitors, agent for preventing or treating TGF β-related diseases.
[claim7]
7. Acting on the cells of the immune system, immune system cells in growth factor and its receptor TGF β to interfere with the reactions, according to claim 6 TGF β of the agent for preventing or treating a disease associated with.
[claim8]
8. To interact with its receptor and TGF β and does not inhibit a reaction by completely, the inhibition of periungual TGF β can be reduced, according to claim 6 or 7 TGF β associated with the agent for preventing or treating the disease.
[claim9]
9. A concentration of 50nm or more in the working Antivenin TGF β and concentration-dependent reaction with the receptor, and a high concentration of 375nm or more in its receptor TGF β completely and does not inhibit reaction, any one of claims 6-8 TGF β of the agent for preventing or treating related diseases.
[claim10]
10. And cancer-related disease TGF β, activating an anti-tumor immunity, associated with any one of claims 6-9 TGF β of the agent for preventing or treating the disease.
[claim11]
11. Cancer cells TGF β secreted from induced by immunosuppressants via T controllability to release the state in the cells, cancer cells with immune cells to restore the attack to the activating, according to claim 10 agent for preventing or treating of.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • MOMOTARO-GENE INC.
  • 発明者(英語)
  • KINOSHITA RIE
  • FUTAMI JUNICHIRO
  • KUMON HIROMI
国際特許分類(IPC)
指定国 (WO2017217556)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close